Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on August 02, 2019, 11:19:53 am
-
Korean scientists have retracted a paper they published last September that found that treating hepatitis B virus (HBV) with Viread (tenofovir disoproxil fumarate) was associated with a lower risk of death or liver transplantation than Baraclude (entecavir), MedPage Today reports. However, research still indicates that hep B treatment with Viread is superior to Baraclude at reducing the risk of hepatocellular carcinoma (HCC, the most common form of liver cancer).
Above all, researchers believe that more investigation—including a thorough meta-analysis of existing data as well as additional observational studies—is needed to sort out what seem to be conflicting signals about which drug is best for treating HBV.
Read more...
https://www.hepmag.com/article/paper-claiming-viread-bests-baraclude-hep-b-treatment-retracted